Lars Fruergaard Jorgensen has led Novo Nordisk through a remarkable period of growth, as demand for its treatments turned the company into one of Europe’s most valuable.
The Danish drugmaker’s rise has reshaped the national economy, making it a central topic in Danish business.
Jorgensen has had to manage the challenges of rapid expansion, from supply constraints to intense scrutiny.
His leadership has placed a Danish company at the centre of a global health story.
